Patient perceptions of copay card utilization and policies

References

• Yang EJ, Galan E, Thombley R, et al. Changes in drug list prices and amounts paid by patients and insurers. JAMA Netw Open. 2020;3(12):e2028510. doi: 10.1001/jamanetworkopen.2020.28510
   PubMed Web of Science ®Google Scholar
• Tichy EM, Hoffman JM, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2022. Am J Health Syst Pharm. 2022;79(14):1158–12. doi: 10.1093/ajhp/zxac102
   PubMed Web of Science ®Google Scholar
• IQVIA Institute for Human Data Science. Medicine spending and affordability in the United States: Understanding patients’ costs for medicines. August 4, 2020. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-spending-and-affordability-in-the-us
   Google Scholar
• American Society of Clinical Oncology. American Society of clinical oncology policy brief: Copay accumulators and copay maximizers. Updated January 21, 2021. Accessed December 23, 2022 Available from: https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/2021-AccumulatorsPolicyBrief.pdf
   Google Scholar
• Ingham M, Song J, Zhao X, et al. Assessment of prevalence and patient characteristics of patients using copay cards and those enrolled in copay adjustment programs. J Manag Care Spec Pharm. 2022;28:S108.
   PubMedGoogle Scholar
• Neilson T, Huynh V, Macdonald A, et al. Financial toxicity of breast cancer care: The patient perspective through surveys and interviews. J Surg Res. 2022;281:122–129. doi: 10.1016/j.jss.2022.08.021
   PubMed Web of Science ®Google Scholar
• Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534–2542. doi: 10.1200/JCO.2010.33.3179
   PubMed Web of Science ®Google Scholar
• Sen AP, Kang SY, Rashidi E, et al. Characteristics of copayment offsets for prescription drugs in the United States. JAMA Intern Med. 2021;181(6):758–764. doi: 10.1001/jamainternmed.2021.0733
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. American Society of clinical oncology position statement: Copay accumulators and copay maximizers. Updated January 21, 2021. Accessed November 17, 2022. Available from: https://old-prod.asco.org/sites/new-www.asco.org/files/content-files/advocacy-and-policy/documents/2021-CopayAccumulatorsStatement.pdf
   Google Scholar
• Dafny L, Ody C, Schmitt M. When discounts raise costs: The effect of copay coupons on generic utilization. Am Econ J Econ Policy. 2017;9(2):91–123. doi: 10.1257/pol.20150588
   Web of Science ®Google Scholar
• Fendrick AM, Buxbaum JD. Precision medicines need precision patient assistance programs. Am J Manag Care. 2019;25(7):317–318.
   PubMed Web of Science ®Google Scholar
• Ingham M, Sadik K, Zhao X, et al. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs. J Manag Care Spec Pharm. 2023;29(9);1084–1092.
   PubMed Web of Science ®Google Scholar
• Brouwer E, Yeung K, Barthold D, et al. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in a mid-size integrated health system. J Manag Care Spec Pharm. 2021;27(6):732–742. doi: 10.18553/jmcp.2021.27.6.732
   PubMed Web of Science ®Google Scholar
• Gangal A, Stoff B. Costly savings: An ethical analysis of copay assistance programs in dermatology. J Am Acad Dermatol. 2021;85(6):1665–1666. doi: 10.1016/j.jaad.2021.04.054
   PubMed Web of Science ®Google Scholar
• Ubel PA, Bach PB. Copay assistance for expensive drugs: A helping hand that raises costs. Ann Intern Med. 2016;165(12):878–879. doi: 10.7326/M16-1334
   PubMed Web of Science ®Google Scholar
• Van Nuys K, Joyce G, Ribero R, et al. A perspective on prescription drug copayment coupons. Updated February 20, 2018. Available from: https://healthpolicy.usc.edu/wp-content/uploads/2018/02/2018.02_Prescription20Copay20Coupons20White20Paper_Final-2.pdf
   Google Scholar
• Walsh BS, Kesselheim AS. CAAP rule and prescription drug prices. Am J Manag Care. 2021;27(8):312–314.
   PubMed Web of Science ®Google Scholar
• Sherman BW, Epstein AJ, Meissner B, et al. Impact of a co-pay accumulator adjustment program on specialty drug adherence. Am J Manag Care. 2019;25(7):335–340.
   PubMed Web of Science ®Google Scholar
• Parekh KD, Wong WB, Zullig LL. Impact of co-pay assistance on patient, clinical, and economic outcomes. Am J Manag Care. 2022;28(5):e189–e197.
   PubMed Web of Science ®Google Scholar
• KFF. 2022 Employer health benefits. October 27, 2022. Available from: https://www.kff.org/report-section/ehbs-2022-section-7-employee-cost-sharing/.
   Google Scholar
• Collins SR, Haynes LA, Masitha R The state of US health insurance in 2022. September 29, 2022. Available from: https://www.commonwealthfund.org/publications/issue-briefs/2022/sep/state-us-health-insurance-2022-biennial-survey#:~:text=Forty%2Dthree%20percent%20of%20working,to%20health%20care%20(23%25).
   Google Scholar
• Fein A Four reasons why PBMs gain as maximizers Overtake copay accumulators. Drug Channels. February 2022. Available from: https://www.drugchannels.net/2022/02/four-reasons-why-pbms-gain-as.html
   Google Scholar
• Nabhan C, Phillips EG Jr, Feinberg BA. How pharmacy benefit managers add to financial toxicity: The copay accumulator program. JAMA Oncol. 2018;4(12):1665–1666.
   PubMed Web of Science ®Google Scholar
• Smalley KB, Warren JC, Barefoot KN. Connection between depression and inability to fill prescriptions in rural FQHC patients with chronic disease. Rural Ment Health. 2016;40(2):113–123. doi: 10.1037/rmh0000051
   PubMedGoogle Scholar
• Brennan TA, Kesselheim AS Accumulators and maximizers: A new front in the battle over drug costs (part 1). Health Affairs Forefront. 2022. November 17. Available from: https://www.healthaffairs.org/content/forefront/accumulators-and-maximizers-new-front-battle-over-drug-costs-part-1
   Google Scholar
• Chandra A, Flack E, Obermeyer Z The health costs of cost-sharing. National Bureau of Economic Research; 2021 Feb 8. Accessed March 22, 2023. https://www.nber.org/system/files/working_papers/w28439/w28439.pdf
   Google Scholar
• Seetasith A, Wong W, Tse J, et al. The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors. J Med Econ. 2019;22(5):414–420. doi: 10.1080/13696998.2019.1580200
   PubMed Web of Science ®Google Scholar
• Patel S, Abreu M, Tumyan A, et al. Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. BMJ Open Diabetes Res Care. 2019;7(1):e000761. doi: 10.1136/bmjdrc-2019-000761
   PubMed Web of Science ®Google Scholar
• Li A, Del Olmo MG, Fong M, et al. Effect of a smartphone application (Perx) on medication adherence and clinical outcomes: a 12-month randomised controlled trial. BMJ Open. 2021;11(8):e047041. doi: 10.1136/bmjopen-2020-047041
   PubMed Web of Science ®Google Scholar
• Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028–3035. doi: 10.1161/CIRCULATIONAHA.108.768986
   PubMed Web of Science ®Google Scholar
• Raghavan D, Keith NA, Warden HR, et al. Levine cancer institute financial toxicity tumor board: a potential solution to an emerging problem. JCO Oncol Pract. 2021;17(10):e1433–e1439. doi: 10.1200/OP.21.00124
   PubMedGoogle Scholar
• Wong WB, Jinnett K. Patient perspectives and use of copayment assistance during the COVID-19 pandemic. J Manag Care Spec Pharm. 2023;29(1):17–23. doi: 10.18553/jmcp.2022.21343
   PubMed Web of Science ®Google Scholar
• Edmonds C, Carver A, DeClercq J, et al. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg. 2022;223(5):975–982. doi: 10.1016/j.amjsurg.2021.09.005
   PubMedGoogle Scholar
• Fudzie SS, Luong B, Jean SJ, et al. Impact of embedded medication assistance program specialists on medication access in outpatient oncology clinics. J Oncol Pharm Pract. 2021;27(8):1829–1834. doi: 10.1177/1078155220970269
   PubMed Web of Science ®Google Scholar
• Jeong AY, Schwartz EB, Roman AR, et al. Characterizing out-of-pocket payments and financial assistance for patients prescribed abiraterone and enzalutamide at an academic cancer center specialty pharmacy. JCO Oncol Pract. 2022;18(2):e284–e292. doi: 10.1200/OP.21.00168
   PubMedGoogle Scholar
• Seymour EK, Daniel L, Pointer E, et al. How to effectively decrease patient co-payments of high-cost drugs through innovation: Lessons from the Karmanos specialty pharmacy. JCO Oncol Pract. 2022;18(1):e137–e151. doi: 10.1200/OP.21.00207
   PubMedGoogle Scholar
• Aviki EM, Thom B, Braxton K, et al. Patient-reported benefit from proposed interventions to reduce financial toxicity during cancer treatment. Support Care Cancer. 2022;30(3):2713–2721. doi: 10.1007/s00520-021-06697-6
   PubMed Web of Science ®Google Scholar
• Shea L, Pesa J, Geonnotti G, et al. Improving diversity in study participation: Patient perspectives on barriers, racial differences and the role of communities. Health Expect. 2022;25(4):1979–1987. doi: 10.1111/hex.13554
   PubMed Web of Science ®Google Scholar
• Chakravarty SD, Abell J, Leone-Perkins M, et al. A novel qualitative study assessing patient-reported outcome measures among people living with psoriatic arthritis or ankylosing spondylitis. Rheumatol Ther. 2021;8(1):609–620. doi: 10.1007/s40744-021-00289-w
   PubMed Web of Science ®Google Scholar
• Garg S, Chewning B, Gazeley D, et al. Patient and healthcare team recommended medication adherence strategies for hydroxychloroquine: Results of a qualitative study informing intervention development. Lupus Sci Med. 2022;9(1):e000720. doi: 10.1136/lupus-2022-000720
   PubMed Web of Science ®Google Scholar
• Hunter WG, Zafar SY, Hesson A, et al. Discussing health care expenses in the oncology clinic: Analysis of cost conversations in outpatient encounters. J Oncol Pract. 2017;13(11):e944–e956. doi: 10.1200/JOP.2017.022855
   PubMed Web of Science ®Google Scholar
• Hunter WG, Zhang CZ, Hesson A, et al. What strategies do physicians and patients discuss to reduce out-of-pocket costs? Analysis of cost-saving strategies in 1,755 outpatient clinic visits. Med Decis Making. 2016;36(7):900–910. doi: 10.1177/0272989X15626384
   PubMed Web of Science ®Google Scholar
• Farano JL, Kandah HM. Targeting financial toxicity in oncology specialty pharmacy at a large tertiary academic medical center. J Manag Care Spec Pharm. 2019;25(7):765–769. doi: 10.18553/jmcp.2019.25.7.765
   PubMed Web of Science ®Google Scholar
• Lee C, Grigorian M, Nolan R, et al. A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. J Med Econ. 2016;19(4):397–402. doi: 10.3111/13696998.2015.1130710
   PubMed Web of Science ®Google Scholar
• Zhu J, Hazen RJ, Joyce C, et al. Local specialty pharmacy and specialty clinic collaboration assists access to hepatitis C direct-acting antivirals. J Am Pharm Assoc. 2018;58(1):89–93.e2. doi: 10.1016/j.japh.2017.10.011
   Google Scholar
• Siegel RD, Slough RG, Crosswell HE, et al. Drug recovery and copay assistance program in a community cancer center: Charity and challenges. J Oncol Pract. 2019;15(7):e628–e635. doi: 10.1200/JOP.19.00016
   PubMed Web of Science ®Google Scholar
• Yezefski T, Steelquist J, Watabayashi K, et al. Impact of trained oncology financial navigators on patient out-of-pocket spending. Am J Manag Care. 2018;24(5 Suppl):S74–S79.
   PubMed Web of Science ®Google Scholar
• Sadigh G, Coleman D, Switchenko JM, et al. Treatment out-of-pocket cost communication and remote financial navigation in patients with cancer: A feasibility study. Support Care Cancer. 2022;30(10):8173–8182. doi: 10.1007/s00520-022-07270-5
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Meeker CR, Doyle JL, et al. Provider and patient burdens of obtaining oral anticancer medications. Am J Manag Care. 2018;24(4):e128–e133.
   PubMed Web of Science ®Google Scholar
• Avalere. State copay accumulator bans impact 11% of US commercial lives. Updated November 11, 2022. Available from: https://avalere.com/insights/state-copay-accumulator-bans-impact-11-of-us-commercial-lives
   Google Scholar
• Inside Health Policy. Copay accumulator battle heats up in congress, states, court. February 14, 2023. Available from: https://insidehealthpolicy.com/
   Google Scholar
• Leung FH, Savithiri R. Spotlight on focus groups. Can Fam Physician. 2009;55(2):218–219.
   PubMed Web of Science ®Google Scholar